Autolus Therapeutics plc (AUTL): Analysts See 697% Upside Potential
A laboratory technician carefully studying a microscope with a biopharmaceutical product inside.
Autolus Therapeutics plc (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company specializing in the development of T-cell therapies for the treatment of cancer and autoimmune diseases. Established in 2014, Autolus is advancing innovative approaches in the field of chimeric antigen receptor (CAR) T-cell therapy, aiming to transform patient outcomes with cutting-edge science and technology.
Autolus has strategically positioned itself to meet global demand through its dedicated commercial manufacturing facility, known as "The Nucleus," located in the UK. This facility not only supports clinical and commercial production requirements but also ensures scalability and flexibility, enabling the company to cater to expanding markets. Autolus retains worldwide commercial rights to its products and maintains a focused marketing strategy targeting key regions such as the United States, the United Kingdom, and Europe. This strategic approach highlights the company's commitment to delivering transformative therapies across diverse geographic markets while ensuring the highest standards of quality in production.
Further analysis of the company's business model and financial performance reflect its significant progress in advancing CAR T-cell therapy. In the first quarter of 2025, Autolus posted revenue of $9 million, demonstrating steady growth. For the full year of 2024, the company reported $45.8 million in revenue, driven by its pioneering efforts in cancer treatment development. With $210 million in cash reserves, Autolus is well-positioned to support the commercialization plans for its therapies and sustain future research and development endeavors. This financial stability has contributed to a positive outlook among analysts, who project the company's share price to reach $9.97 within the next twelve months, offering an upside potential of 697.60%. Through its relentless pursuit of innovation and financial health, Autolus Therapeutics plc remains at the forefront of oncology treatment, pushing boundaries and redefining possibilities in CAR T-cell therapy.
Overall, Autolus Therapeutics plc (NASDAQ:AUTL) ranks 3rd on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of AUTL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AUTL and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy
Disclosure: None. This article is originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
ACHV: Achieve's Busy Day
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted a flurry of press releases last week announcing the submission of its new drug application (NDA), a partnership with Omnicom for cytisinicline commercialization, a proposed public offering and the pricing of the offering. The capital raise was closed on June 30th. This is the culmination of more than a decade of work developing cytisinicline for smoking cessation. Now that the development phase of cytisinicline for smoking cessation is coming to a close, we look towards the regulatory and commercialization phases. We expect to see the FDA formally accept the NDA by late August and Achieve's management team to turn its attention towards the sales effort. Assuming normal turnaround times, we expect the FDA to set a target action date sometime in 2Q:26. NDA Submission Achieve announced its NDA submission of cytisinicline for smoking cessation in a June 26th press release. The company conducted two Phase III studies, an open label safety study and other studies that evaluated over 2,000 participants with the results demonstrating the safety, efficacy and tolerability of cytisinicline. We expect to see acceptance of the NDA within 60 days and further expect additional safety data from the ongoing ORCA-OL trial to be shared with the agency near year end. Commercialization Partnership Now that the new drug application has been submitted, Achieve is further advancing its commercialization efforts. During its earnings calls, the company has outlined its commercialization strategy and is now partnering with Omnicom Group to execute the plan. Omnicom Group provides brand and advertising services to thousands of clients globally and is one of the world's largest advertising and marketing services companies. Achieve will work with Omnicom subsidiary Credera, which is focused on digital transformation services. Credera combines consulting, artificial intelligence (AI) and technology expertise to build consumer technology platforms, integrate marketing technology systems and provide strategic consulting services. It will help Achieve to precisely target and engage healthcare professionals and patients through optimization of channel performance and acceleration of meaningful engagement. The team executing the initiative will include Goodby, Silverstein & Partners, DDB Health, and Ketchum Health which are health care-focused subsidiaries of the Omnicom marketing group. The various subsidiaries will provide expertise in consumer brand development, medical education and strategic public relations and communications, applying industry insights to support cytisinicline launch. In the Achieve partnership, Ketchum Health brings public relations and communications expertise, while Credera handles technology, Goodby Silverstein provides creative advertising, and DDB Health focuses on healthcare marketing. The partnership will use generative AI, predictive analytics and social listening to enhance targeting and personalization. Using a comprehensive approach, it will also employ healthcare applications, pharmacies and data providers to expand the reach and depth of insights. Omnicom has worked as media agency, digital and brand experience for other pharmaceutical and biotechnology clients including established firms such as AbbVie, AstraZeneca, Novartis and Moderna among others. Achieve will be the first small company that Omnicom has supported in commercializing a newly approved drug. Therefore, Omnicom will take on a broader strategic role than in its past partnerships. The Omnicom team will help communicate the optimal message to the provider and patient and monitor its effectiveness in real time. This will allow for rapid course corrections and focus on high value activities. Achieve has identified several target groups for its marketing efforts that are stratified by age, social media use and other demographic data. It was able to identify these groups based on subject experiences in the company's many clinical trials. We anticipate that the structure of Achieve's internal marketing team will be heavily tilted toward supporting the digital campaign with contract representatives available for in-person physician meetings when appropriate. Public Offering On June 30th, 2025 Achieve closed its $45 million capital raise. 15 million shares were issued at $3.00, each of which included an attached warrant exercisable at $3.00 per share. An additional 1,766,666 warrants were issued upon the partial exercise by the underwriters of their option to purchase additional shares, bringing total issued warrants to approximately 16.8 million. Net proceeds from the capital raise are estimated to be $41.3 million as disclosed in the June 27th Form 8-K filing. ORCA-OL Safety Trial Achieve began 2025 by announcing that 300 participants had completed six months of treatment in the Ongoing Research of Cytisinicline for Addiction Program, Open Label (ORCA-OL) trial. The Data Safety Monitoring Committee (DSMC) identified no safety concerns as of this milestone allowing registrational filing with the FDA. As of May 2025, a third DSMC safety review was completed which also found no unexpected treatment-related adverse events. As of the first quarter reporting date, more than 100 subjects had completed one year of cytisinicline treatment. Furthermore, about 75% of the 479 (~360) individuals remained on treatment in the trial. We think that it is a material real-world positive that so many participants would remain on a smoking cessation product for that long a period suggesting that cytisinicline is well tolerated. This is particularly notable given the high discontinuation rates for Chantix and the associated unpleasant side effects such as nausea, headache, abnormal dreams and constipation.[1] Achieve expects to complete the one-year safety data package in the next few months and will submit this to the FDA by the 120-day safety review milestone. This should be around year-end 2025. Achieve expects that it will far exceed the 100-patient minimum required for one year of safety observations and could see as many as 300 patients with one year of exposure. Since one of the secondary endpoints is efficacy, this study should be able to show a wealth of data that can help providers use cytisinicline more effectively especially in chronic areas of disease such as Chronic Obstructive Pulmonary Disease (COPD) and cardiology. Milestones Development of cytisinicline product label for smoking cessation – 1H:25 Completion of six months of ORCA-OL safety data for 300 subjects – January 2025 Attendance at Oppenheimer Healthcare Life Sciences Conference, Virtual – February 2025 Attendance at Barclays Healthcare Conference, Miami – March 2025 Selection of 3rd party logistics partner – 2Q:25 NDA Submission – 2Q:25 FDA data submission from patients with twelve months of exposure to cytisinicline – 4Q:25 Launch of Phase III vaping trial – 1H:26 FDA target action date for cytisinicline NDA – 1H:26 Launch of cytisinicline – 3Q:26 SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer . ________________________ [1] Minian, N., et al. Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review. BMC Public Health. March 2024.
Yahoo
5 hours ago
- Yahoo
This $11.5M Startup Backed By Niklas Zennström Wants To Help You Launch A Million-Dollar AI Business From Your Sofa
Henrik Werdelin, co-founder of BarkBox and longtime startup advisor, has launched a new venture named Audos, which recently raised $11.5 million in seed funding led by True Ventures. Other investors include Offline Ventures, Bungalow Capital, and notable angel investors Niklas Zennström and Mario Schlosser, TechCrunch reports. Based in New York, Audos offers AI tools and startup-building support to everyday people who want to launch small businesses without any technical background. Unlike accelerators or traditional venture models, TechCrunch says that Audos charges a 15% perpetual revenue share instead of taking equity from founders. Don't Miss: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — Werdelin, who previously built startup studio Prehype, told TechCrunch that Audos combines years of startup-building expertise into an accessible platform anyone can use to launch a digital product. "What we're trying to do is to figure out how you make a million companies that do a million dollars [in annual revenue]," Werdelin said. That goal, if realized, would create what he calls a trillion-dollar turnover business, a term that sets a new benchmark for bottom-up innovation. The company uses social media platforms like Instagram and Facebook to reach potential founders and identify whether their business ideas can generate customers at a sustainable cost. According to TechCrunch, Audos's AI agent interacts with users directly, helping them clarify their offer and go to market quickly using natural language inputs. Trending: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — So far, Audos has supported the launch of what Werdelin calls "low hundreds" of businesses in its beta phase, TechCrunch reports. These include ventures like a virtual golf swing coach, an AI nutritionist, a mechanic offering quote evaluations, and even an "after-death logistics" consultant. Each founder received up to $25,000 in funding, access to Audos's proprietary tools, and support in distributing their offer through paid social ads. According to TechCrunch, Werdelin refers to these micro-businesses as "donkeycorns," signaling modest yet profitable ventures that aim to support personal freedom rather than billion-dollar exits. According to TechCrunch, Audos's model may spark discussion over the long-term cost of a 15% revenue share, which continues indefinitely like Apple's (NASDAQ:AAPL) App Store platform fee. While some entrepreneurs may welcome the no-equity route, others could see the permanent cut as a costly tradeoff over acknowledged that the market is rapidly filling with similar AI tools, saying, "the world is full of these tools" and they are "getting better rapidly," TechCrunch says. Audos distinguishes itself by helping non-technical users go to market quickly using natural language prompts and social media targeting. True Ventures partner Tony Conrad expressed confidence in Audos, citing its potential to support thousands who want to start small, independent businesses with real revenue potential. "There are just lots and lots of people" who need this opportunity, Conrad told TechCrunch. Audos currently operates with just five employees but aims to expand its impact exponentially without building a large internal team. Werdelin believes the next wave of entrepreneurship should be built by people previously left out of the ecosystem. "We believe that the world is better with more entrepreneurship," he told TechCrunch, pointing to mom-and-pop shops as his inspiration rather than venture-backed unicorns. Read Next: Here's what Americans think you need to be considered wealthy. Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article This $11.5M Startup Backed By Niklas Zennström Wants To Help You Launch A Million-Dollar AI Business From Your Sofa originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Why AppLovin Stock Slumped in June
Outside development put the hurt on the specialty tech company's shares. One, a highly critical report published by a short-seller, was especially hurtful. 10 stocks we like better than AppLovin › Last month, AppLovin (NASDAQ: APP) was punished by investors more for what it didn't do than for what it actually did. A hoped-for graduation to a top stock index was one of the non-occurrences, while a short-seller felt compelled to write a scathing report on the company. In some respects, AppLovin was fortunate that its stock didn't decline more deeply than the sub-11% dip it experienced across June. The index let-down, such as it was, occurred near the top of the month. Every quarter, S&P Dow Jones Indices, the operator of the closely followed S&P 500 index (among many others), likes to "rebalance" the index, replacing component stocks deemed no longer suitable with new ones. Several days ahead of the current rebalancing, speculation grew about which companies would land on the hallowed index. AppLovin was mentioned as one of those candidates, at least by a team of analysts at heavyweight lender Bank of America. The leading prospect, in their take, was online securities brokerage Robinhood Markets, but it also mentioned six other prospects. Among these was AppLovin. Alas, S&P Dow Jones Indices performed what felt like a head fake, electing not to change the composition of the S&P 500 index at all this time. The market can usually shrug off a non-event like this, disappointing as it may be initially. It's tougher to ignore a highly critical and detailed analysis of a stock, such as the ones typically published by institutional short-sellers. Unfortunately for AppLovin, that's exactly what happened when such a firm trained its sights on the company. In mid-June, the firm, Culper Research, unveiled a rather sprawling 30-page screed criticizing AppLovin's business practices. Many of its accusations pertained to AppLovin's goal of acquiring the non-Chinese operations of controversial social media video app TikTok, a service that has fallen afoul of the U.S. government. In the report, Culper intimated that a significant AppLovin shareholder, Hao Tang, is an individual with a shady past and "extensive direct and indirect ties" to certain dark corners of the Chinese government. It decried this "covert Chinese ownership," and warned of the danger posed to U.S. national security. AppLovin hasn't made any official statement on the Culper Research allegations. Perhaps, management feels they'll blow over with investors before long. Personally, I'd view that as a mistake since troubling allegations like the ones the short-seller raises have a way of lingering and, in turn, negatively affecting investor morale. We'll see whether the company can deliver news encouraging enough to dislodge the numerous accusations from the collective investor memory. Before you buy stock in AppLovin, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AppLovin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Bank of America is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AppLovin and Bank of America. The Motley Fool has a disclosure policy. Why AppLovin Stock Slumped in June was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
